The emergence of new diseases, changes in lifestyle, social evolution, the complexity of technological resources as well as many other factors, makes research of new therapeutic solutions an ever pressing necessity.

By the 1990s, we began our Research and Development (R&D) project. In the last decade we saw the birth of our own medicines. We are building our way into research inspired by our strong motivation: Keeping life in mind.

The BIAL Group invests over 20% of its turnover in R&D. This is our major pledge: we are committed to discovering and developing innovative medicines.

Our R&D centre in Portugal is staffed by international teams of highly qualified people. It comprises chemists, pharmacologists, biochemists, physicians and pharmacists, all of whom are dedicated to finding new drugs, in two major areas of research: neurosciences and cardiology.

Our scientific team centralizes all the areas involved in the process of finding new medicinal products: chemical, pharmacological and clinical investigation. We collaborate with investigators and scientists from universities, industry and research centers to deliver the best solutions to health professionals, patients and their families.

In recognition of BIAL's commitment to research and development, the group is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the respected federation of leading research firms in the European pharmaceutical sector.

Recently, BIAL established a new affiliate in the United States of America, BIAL Biotech Investments Inc (BIAL Biotech). BIAL Biotech is a research center of excellence for the development of genetically-defined Parkinson’s disease therapeutics. With this acquisition, BIAL is expanding its pipeline, namely with the integration of new compounds in neurodegeneration already in clinical development, specifically for Parkinson's Disease, where the company already has a significant market position.

R&D and innovation principles

We see Research and Development as a strategic area for the group. We are pledged to manage knowledge and innovation to develop, in a systematic and sustained manner, internationally competitive therapeutic solutions that merit acceptance from the scientific community, regulatory authorities and the market and which, as a consequence deliver value to the company and to its shareholders, employees, medical fraternity, consumers and other business partners.

This commitment will be fulfilled, throughout the Company, by adhering to some principles:

  • Organization and administration of the RDI management system, so that its working groups produce ground-breaking ideas that can become projects that could generate value for the market.
  • Ensuring proper planning, execution and control of projects and a judicious provision of resources in strict observance of and compliance with the regulatory, technical and normative requirements which apply to our business operations
  • Fostering the motivation, creativity and upskilling of employees so as to constantly promote a culture of rigour and an environment in which scientific and technological knowledge is generated.
  • Continuously improving the effectiveness of the RDI management system, to maximizing the return on available resources and ensure the assessment and promotion of the results.